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PENGGUNAAN PROTEIN ANTI-BAKTERIA DARIPADA 
LACTOBACILLUS PLANTARUM SEBAGAI BAKTERIOCIDESTERHADAP 
STAPHYLOCOCCUS AUREUS 
ABSTRAK 
Empat puluh tiga strain bakteria asid laktik telah diasingkan dan dikenalpasti 
daripada sayur-sayuran segar, buah-buahan segar dan produk penapaian. Supernatan 
bebas sel (CFS) Lactobacillus plantarum USM8613 (L. plantarum USM8613) yang 
telah dineutralkan yang menunjukkan kesan rencatan lebih kuat (P<0.05) terhadap 
Staphylococcus aureus (S. aureus) berbanding semua strain yang dikaji telah dipilih 
untuk analisis seterusnya. CFS L. plantarum USM8613 telah diasingkan kepada 
fraksi protein, polisakarida dan lemak, dengan semua fraksi merencat S. aureus 
secara lebih ketara (P<0.05), dengan kesan yang lebih menonjol daripada fraksi 
protein mentah. Kajian permukaan plasmon resonans menunjukkan fraksi protein 
mentah mempunyai kecenderungan ikatan yang kuat terhadap S. aureus dan 
morfologi membran kedutan dan kasar diperhatikan dalam S. aureus yang dirawat 
dengan fraksi protein mentah melalui imbasan mikroskop elektron. Fraksi protein 
mentah telah ditulenkan lagi untuk kehomogenan dengan kaedah penulenan tiga 
langkah. Dua protein antimikrob anggapan yang ditetapkan sebagai Fraksi A dan 
Fraksi B masing-masing telah ditemui dan dikenalpasti sebagai enzim 
transglikosilase ekstrasel dan gliseraldehid-3-fosfat dehidrogenase. Ketiga-tiga fraksi 
protein (A, B dan A+B) daripada L. plantarum USM8613 menunjukkan kesan 
bakterisidal terhadap S. aureus, dengan Fraksi A mempunyai aktiviti anti-
stafilokokal yang lebih kuat. Kedua-dua fraksi A dan B mempunyai mekanisme anti-
stafilokokal yang berbeza. Fraksi A memusnahkan peptidoglikan dinding sel S. 
aureus. Sementara itu, Fraksi B menembusi sel S. aureus dan kemudiannya 
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menyebabkan autolysis S. aureus melalui induksi ekspresi lebihan regulator autolisis, 
gen sigB, mgrA dan atl. Akibatnya, Fraksi A dan Fraksi B menyebabkan penelapan 
membran dalam S. aureus. Fraksi A dan Fraksi A+B melesapkan potensi membran, 
meningkatkan pengoksidaan membran lipid, mengubah sifat berubah-ubah membran 
dan meningkatkan kebocoran kandungan intrasel dalam S. aureus. Ini menunjukkan 
Fraksi A mempunyai kesan gangguan membran sel secara langsung dan lebih kuat 
terhadap S. aureus dan seterusnya meningkatkan tindakan Fraksi B. Ketiga-tiga 
fraksi protein (A, B dan A+B) adalah tidak sitotoksik kepada sel HaCaT pada semua 
kepekatan yang dikaji (100-12800 AU/ml). Ketiga-tiga fraksi protein antimikrob 
melindungi (P<0.05) sel HaCaT yang dijangkiti oleh S. aureus daripada serangan S. 
aureus berterusan dan meningkatkan pembiakan sel HaCaT. Ketiga-tiga fraksi 
protein antimikrob mempunyai kesan anti- inflamasi setelah penghapusan bakteria. 
Di antara kesan anti- inflamasi ini ialah kekurangan secara ketara (P<0.05), ekspresi 
dan penghasilan reseptor-2 seakan tol (toll- like receptor-2, TLR-2), β-defensin 
(hBDs) dan sitokin pro- inflamasi (IL-1α, IL-1β, IL-6, TNF-α dan IL-8). Secara 
kolektifnya, hasil kajian ini menunjukkan keberkesanan dan potensi terapeutik 
protein antimikrob daripada L. plantarum USM8613 untuk memerangi S. aureus, 
seterusnya dapat digunakan sebagai agen anti-stafilokokal alternatif dalam industri 
dermatologi untuk rawatan jangkitan kulit stafilokokal. 
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DEVELOPMENT OF LACTOBACILLUS PLANTARUM ANTIBACTERIAL 
PROTEINS AS BACTERIOCIDES AGAINST STAPHYLOCOCCUS AUREUS 
ABSTRACT 
 Forty-three strains of lactic acid bacteria (LAB) were isolated and identified 
from fresh vegetables, fresh fruits and fermented products. Neutralised cell- free 
supernatant (CFS) of Lactobacillus plantarum USM8613 (L. plantarum USM8613) 
exerted the strongest inhibitory effect (P<0.05) against Staphylococcus aureus (S. 
aureus) compared to all LAB strains studied. Thus, it was selected for subsequent 
analyses. CFS of L. plantarum USM8613 was fractionated into protein, 
polysaccharide, and lipid fractions. All three fractions significantly inhibited S. 
aureus (P<0.05), but the most profound inhibitory effect was from the crude protein 
fraction. Surface plasmon resonance study demonstrated strong binding affinity of 
the crude protein fraction to S. aureus and rough and wrinkled membrane 
morphology was observed in S. aureus, treated with crude protein fraction via 
scanning electron microscopy. The crude protein fraction was further purified to 
homogeneity by a three-step purification method. Two putative antimicrobial 
proteins, designated as Fraction A and Fraction B, were discovered and identified as 
extracellular transglycosylase and glyceraldehyde-3-phosphate dehydrogenase 
respectively. Individual fractions A and B, and combined fraction A+B from L. 
plantarum USM8613 exerted a bactericidal effect against S. aureus, with a stronger 
anti-staphylococcal activity from Fraction A, suggesting Fraction A and Fraction B 
have different anti-staphylococcal mechanisms. Fraction A degraded the cell wall 
peptidoglycan of S. aureus. Meanwhile, Fraction B penetrated S. aureus cells and 
subsequently caused S. aureus autolysis via induction of overexpression of autolysis 
regulators−sigB, mgrA and atl genes. Consequently, both Fraction A and Fraction B 
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caused membrane permeabilisation in S. aureus. Fraction A and Fraction A+B 
prevalently dissipated the membrane potential, induced membrane lipid peroxidation, 
altered membrane fluidity, and enhanced leakage of intracellular contents of S. 
aureus, suggesting Fraction A exhibited a direct and stronger cell membrane 
disruptive effect against S. aureus, thereby enhancing the action of Fraction B. 
Fraction A, Fraction B, and Fraction A+B did not exhibit cytotoxicity effects on 
HaCaT cells at all concentrations studied (100-12800 AU/ml). These antimicrobial 
proteins significantly (P<0.05) protected S. aureus-infected HaCaT cells from 
continued S. aureus invasion and enhanced HaCaT cell proliferation. These 
antimicrobial proteins exerted anti- inflammatory effect upon bacterial clearance, 
where the expression and production of toll- like receptor-2 (TLR-2), β-defensins 
(HBDs), and various pro- inflammatory cytokines (IL-1α, IL-1β, IL-6, TNF-α, and 
IL-8) were significantly reduced (P<0.05). Collectively, results obtained illustrated 
that the therapeutic potential of the antimicrobial proteins from L. plantarum 
USM8613 to combat S. aureus and could be applied as alternative anti-
staphylococcal agents in the dermatological industry to treat staphylococcal skin 
infections.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Lactic acid bacteria (LAB) are gram-positive, catalase-negative, immobile, 
non-sporulating, aerotolerant cocci or rods that produce lactic acid as their main 
metabolic end product during carbohydrate fermentation (Khalid, 2011). LAB are 
mainly divided into four genera: Lactobacillus, Lactococcus, Leuconostoc and 
Pediococcus. They are normally used in dairy products, meat, vegetables, cereals, 
and wine fermentation. LAB are generally regarded as safe under the US Food and 
Administration (FDA) guidelines and in recent years they have been renowned for 
their health promoting effects and some were claimed with probiotic properties 
(Patrick, 2012). LAB, particularly members of the genus Lactobacillus, have 
traditionally been documented to confer beneficial effects on gut health including 
modulation of unbalanced indigenous microbiota, reduction of gastro- intestinal 
discomfort, and prevention and treatment for diarrhea and irritable bowel syndrome 
(Collado et al., 2009). Recently, LAB have drawn attention for their capabilities to 
exert therapeutic functions beyond the gut, for instance the skin.  
The human skin is the largest organ of human body that functions as an 
important barrier preventing the escape of moisture and protecting human body from 
invasion and growth of infectious bacteria (Segre, 2006). It is an intr icate habitat for 
enormous variability of microbial communities. The skin is colonised by a diverse 
population of microbes, many of which are commensal or symbiotic, during birth 
and in subsequent post-natal exposure. The skin microbiota is mainly comprised of 
Staphylococcus sp., Micrococcus sp., Corynebacterium sp., and Propionibacterium 
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sp. (Chiller et al., 2001). They are beneficial for a healthy person, which supplement 
the barrier function of the skin by inhibiting the growth of pathogenic species and 
maintain skin balance. However, some of the skin microbiota may become 
pathogenic to an impaired skin barrier or in an immuno-compromised person. 
Staphylococcus aureus, which is an opportunistic pathogen that resides and colonises 
on human skin and mucous membrane, plays an undeniable role in human skin 
infections. 
S. aureus is a common commensal of humans and its primary site of 
colonisation is anterior nares and the skin (Plata et al., 2009). Colonisation 
predisposes an individual to S. aureus infections as it provides a reservoir from 
which bacteria can be introduced when host defenses are breached (Kluytmans et al., 
1997). S. aureus causes a wide array of staphylococcal infections ranging from 
minor skin infections such as impetigo, folliculitis, furuncle, and abscesses to 
invasive and life-threatening diseases including septic arthritis, osteomyelitis, 
pneumonia, meningitis, septicaemia and endocarditis (Lowy, 1998; Foster, 2005; 
Iwatsuki et al., 2006). In recent years, S. aureus has received great attention due to 
its intrinsic virulence and the emergence of the antibiotic resistant variants that are 
increasingly resistant to a vast number of antimicrobial agents. Several newer agents 
against the antibiotic-resistant virulent strains have recently been discovered or under 
clinical development, yet resistance to these new classes of antibiotics has already 
been reported (Ruiz et al., 2002; Aksoy and Unal, 2008). Inevitably, this has left 
fewer effective bactericidal antibiotics to fight against this often life-threatening 
causative agent and therefore a paradigm shift in the treatment of staphylococcal skin 
infection is necessary to prevent antibiotics becoming obsolete. Decolonisation of S. 
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aureus and treatment of its skin infections via non-antibiotic measures ought to be 
considered.    
The increasing interest in treating bacterial skin infection in a natural way has 
intensified the use of LAB as a feasible biotherapeutic alternative. LAB have been 
proposed to augment the skin barrier function to inhibit skin pathogens, prevent or 
treat bacterial skin infections, and promote skin health by either or both competitive 
exclusion and production of antimicrobial substances (Gan et al., 2002; Gueniche 
and Castiel, 2009; Charlier et al., 2009). For instance, Prince et al. (2012) have 
demonstrated that Lactobacillus reuteri inhibited S. aureus adherence and protected 
epidermal keratinocytes from S. aureus- induced cell death by competitive exclusion. 
Whilst either live bacteria or lysate of L. rhamnosus GG have been reported to 
inhibit the growth of S. aureus and reduce bacterial adhesion on epidermal 
keratinocytes. However, the safety of using live bacteria, especially in situations 
where the skin barrier is breached remains an important concern. In fact, the 
application of viable bacteria to wounds can lead to the risk of bacteraemia. Study 
has suggested that LAB metabolites such as the bacteriocin, nisin F can potentially 
treat subcutaneous skin infections caused by S. aureus (De Kwaadsteniet et al., 
2010). For this reason, the inhibitory substances produced by LAB may be the 
preferred choice. 
Considering the increasing levels of antibiotic resistance in S. aureus remains 
as a serious problem to public health and it is essential to seek for a better alternative, 
we hypothesised that LAB could be an interesting biotherapeutic agent. The 
inhibitory substances produced by LAB can potentially inhibit S. aureus and/or treat 
staphylococcal skin infections. Moreover, the anti-staphylococcal activity and the 
mechanisms of the potential inhibitory substances produced by LAB remains to be 
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elucidated. In addition, the efficacy and immuno-modulating effects of the inhibitory 
substances on human skin are scarcely reported. Thus, in depth investigation is 
needed to acquire a better understanding on how LAB inhibitory substances interfere 
with the skin pathogenic bacteria, S. aureus and promote skin health.  
 
1.2 Aim and Objectives for Research 
 The main aim of this study is to evaluate the effects of inhibitory substances 
from LAB against the skin pathogen, S. aureus.  
 
Specific and measurable objectives were: 
1. To isolate, identify and select a potential strain of LAB that produces inhibitory 
metabolites against S. aureus 
2. To fractionate, characterise and evaluate the potential LAB inhibitory metabolites 
against S. aureus 
3. To purify and characterise the putative anti-staphylococcal compounds from the 
fractionated cell-free supernatant of LAB 
4. To elucidate the mechanisms of action of the purified putative anti-staphylococcal 
compounds of LAB against S. aureus 
5. To evaluate the protective effect, efficacy and immuno-modulating effect of the 
purified putative anti-staphylococcal compounds of LAB on human keratinocytes 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 LAB 
 LAB are a group of non-motile and non-spore forming Gram-positive 
bacteria.  They ferment carbohydrate and produce lactic acid as the major end-
product (Wong et al., 2014; Nair and Surendran, 2005). Members of the genera 
Lactobacillus, Lactococcus, Enterococcus, Leuconostoc, Pediococcus  and 
Streptococcus are commonly recognised as lactic acid producing bacteria (Jay, 2000; 
Holzapfel et al., 2001). LAB are nutritionally fastidious in nature as they require rich 
media to grow. Hence, LAB are widely distributed in niches with rich nutrient 
supplies such as humans, animals, dairy products, meats, plants, vegetables, fruits, 
beverages, fermented products, and sewage (König and Fröhlich,  2009). 
 Fresh fruits and vegetables are essential components of the human diet and 
natural habitats for various beneficial LAB. For instance, L. plantarum has been 
successfully isolated from olives, pineapple, papaya, and grapefruit juice and found 
to exert antimicrobial activity against several spoilage bacteria, including 
Staphylococcus aureus (Kato et al., 1994; Todorov and Dicks, 2005; Todorov et al., 
2011; Wong et al., 2014). Moreover, various LAB with probiotic characteristics 
have also been isolated from fermented products. The presence of LAB in fermented 
products also improves the safety, nutritional values, and sensory properties of the 
foods (Lucke, 2000; Papamanoli et al., 2003). Examples include L. sakei, L. curvatus, 
and L. plantarum strains which have been successfully isolated from naturally 
fermented dry sausages and found to exert antimicrobial activity against common 
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food spoilage bacteria, Listeria monocytes and Staphylococcus aureus (Papamanoli 
et al., 2003).  
 LAB have been well-documented for their important technological properties 
in food production which increase the nutritional values, aroma, texture and shelf-
life of the foods (Lebeer et al., 2008). The preservative effect of LAB is mainly due 
to the production of antimicrobial substances such as organic acids, hydrogen 
peroxide, diacetyl, bacteriocins, and bacteriolytic enzymes (Klaenhammer 1988; 
Stiles and Hastings, 1991). In addition, LAB are also incorporated into food and 
beverages products as dietary adjuncts to promote gastrointestinal health and 
improve gut immune functions (Marini and Krugman, 2012). Numerous studies have 
revealed the potential use of LAB to offer benefits beyond the gut. This includes 
improving lactose intolerance, preventing gut inflammation, enhancing natural 
immunity, and reducing serum cholesterol and colon cancer (Liu et al., 2007).  
 
 2.1.1 Lactobacillus 
 The genus Lactobacillus is a group of Gram-positive, rod-shaped, catalase-  
negative, non-motile, and non-sporulating microorganisms with genomic guanine-
cytosine content that varies from 32 to 51 % (Otieno, 2011). The genus 
Lactobacillus is a very diverse genus with 185 recognised species and 28 subspecies 
identified to date (Euzeby, 2013).  
 Lactobacilli have different fermentation characteristics and produce lactic 
acid as the major metabolic acid. They can be divided into three classes, namely 
obligate homofermentative, facultative heterofermentative, and obligate 
heterofermentative (Tham et al., 2011). Various studies have reported that 
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Lactobacillus species such as L. gasseri, L. reuteri, and L. rhamnosus are the most 
dominant bacteria in the gastrointestinal tract and oral cavity (Reuter, 2001; Saito, 
2004). Moreover, Lactobacillus species are also widely distributed in ubiquitous 
environments rich- in carbohydrates such as fruits, vegetables, plants, beverages, 
dairy products, fermented foods, and sewage (Giraffa et al., 2010). Clinical 
evidences have demonstrated the potential use of lactobacilli in foods and beverages 
for human consumption due to their ability to improve food quality and promote 
human health (Reid et al., 2003). 
 
 2.1.2 Conventional Health Benefits 
 LAB have been long used in food fermentation since the discovery of their 
preservative and beneficial effects on gastrointestinal health. It is crucial to maintain 
gastrointestinal health as the gastrointestinal tract contains approximately 70 % of 
the immune cells of the entire immune system (Vighi et al., 2008). LAB, commonly 
found in healthy intestinal microflora, interact with both the innate and adaptive 
immune systems to exert health promoting effects on the host (Purchiaroni et al., 
2013). 
 LAB are well-known for their antimicrobial effects. LAB have been shown to 
produce surface active components that inhibit the adhesion of other pathogenic 
bacteria while facilitate them to adhere to the small intestine (Pereira et al., 2003). 
LAB can also exert antimicrobial effects via the production of antimicrobial 
metabolites such as organic acids, hydrogen peroxide, and bacteriocins. The 
production of lactic acid, for example, lowers the environmental pH and thus further 
inhibits the growth of pathogens (Fayol-Messaoudi et al., 2005).  The antimicrobial 
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effect of hydrogen peroxide is due to its strong oxidising nature. Studies have shown 
that hydrogen peroxide produced by L. gasseri and L. johnsonii NCC33 inhibited the 
growth of both Gram-positive S. aureus and Gram-negative Salmonella sp. 
(Pridmore et al., 2006; Otero and Nader-Macias, 2006). Bacteriocins are one of the 
major antimicrobial metabolites from LAB. One study has demonstrated that 
plantaricin ZJ008 by L. plantarum ZJ008 formed pores and caused leakage of K+ 
out of the cells of various Staphylococcus spp., including the methicillin- resistant 
strains (Zhu et al., 2014). 
 Besides secreting antimicrobial metabolites, LAB can also stimulate the host 
immune response against pathogen invasion. The outer membrane of LAB, 
consisting mostly of peptidoglycan and lipoteichoic acid, enhances the host innate 
immunity response. Both peptidoglycan and lipoteichoic acid are detected by host 
toll- like receptor-2 (TLR-2) and peptidoglycan recognition protein, subsequently 
initiating innate immune response in which pro- inflammatory cytokines and 
secretory immunoglobulin A (sIgA) are produced (McDonald et al., 2005; 
Warchakoon et al., 2009; Brandt et al., 2013). The cytokines employ chemotactic 
mechanisms upon encounter with pathogens while sIgA prevents the binding and 
penetration of foreign invaders to the epithelia cells (Erickson and Hubbard, 2000). 
The interaction between LAB peptidoglycan and peptidoglycan recognition proteins 
act as antibacterial molecules which activates either of the two-component systems, 
CssR-CssS or CpzA-CpxR. This activation results in events responsible for cell 
death such as membrane depolarisation, oxidative stress, and inhibition of RNA, 
DNA, and cell wall synthesis (McDonald et al., 2005; Park et al., 2011). Claes et al. 
(2012) have reported that lipoteichoic acid isolated from L. rhamnosus GG induced 
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intestinal IL-8 production and NF-kB activation via TLR-2 or TLR-6 interaction, 
thereby enhanced the pro-inflammatory activities in HEK293T cells. 
 LAB are able to produce β-galactosidase, phospho-β-galactosidase, and 
phospho-β-glucosidase enzymes that digest lactose in dairy products into glucose 
and galactose, through activation of the two lactose transportation systems, namely 
the lactose-permeate transportation and lactose-specific phosphoenolpyruvate-
dependent phosphotransferase systems, and subsequently alleviate lactose 
intolerance symptoms (Honda et al., 2007). Upon ingestion of sufficient amount of 
lactose, lactose maldigesters may experience various symptoms which include 
abdominal discomfort, bloating, diarrhoea, and flatulence (Vesa et al., 2000). One 
study has shown that the consumption of L. acidophilus- and L. casei-fermented 
milk successfully reduced the development of gastrointestinal discomfort, and 
suppressed intestinal motility as well as hydrogen gas production in 18 lactose 
deficient patients (Gaón et al., 1995).  
 LAB have also been demonstrated to ease antibiotic-associated diarrhoea and 
inflammatory diseases such as ulcerative colitis and Crohn’s disease. This was 
achieved by regulating the intestinal microbiota and stabilising antibiotic- induced 
dysbiosis as demonstrated by Lactobacillus GG (Zhang et al., 2005). Three possible 
mechanisms of LAB to inhibit growth of pro- inflammatory intestinal pathogens are 
through the production of inhibitory substances, adherence to mucosal layers, and 
iron-siderophores (Fung et al., 2011).  
 Several studies have demonstrated the anti-carcinogenic effects of LAB. 
Liong (2008) suggested that the short-chain fatty acids from LAB lowered the 
colonic pH, and suppressed the growth of tumor-promoting and pro-carcinogenic 
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pathogenic microorganisms. In addition, LAB have been shown to possess anti-
neoplastic activity for the prevention of colorectal cancer (Boyle et al., 2006). The 
anti-carcinogenic activity of LAB was achieved via enhancement of intestinal 
detoxification and transit immune status, as well as suppression of as-
p21oncoprotein expression (Singh et al., 1997; Cabana et al., 2007). Other studies 
suggested that the anti-carcinogenic effect of LAB was attributed to the binding of 
the cell wall skeleton of LAB and heterocyclic amines by intestinal probiotics to the 
mutagens (Zhang and Ohta, 1991; Orrhage et al., 1994). In one such study, the 
administration of LAB alleviated the aberrant crypt foci counts in carcinogen-
induced rats via the suppression of nitroreductase and β-glucoronidase activities 
(Verma and Shukla, 2013). Another study by Rafter et al. (2007) demonstrated that 
the secretion of IL-12 was significantly increased, the faecal flora was changed, and 
the production of genotoxins, colorectal proliferation and the capacity of faecal water 
to induce necrosis in colonic cells were decreased in 43 polypectomized patients 
after consuming symbiotic food containing L. rhamnosus LGG and B. lactic BB12. 
 LAB are also well-known for their serum cholesterol lowering ability. Shah 
(2007) reported that the administration of probiotic fermented milk (109 bacteria per 
mL) significantly reduced 50 % of the serum cholesterol level in 
hypercholesterolaemic human subjects. The hypocholesterolaemic effect of LAB 
was attributed to the ability of LAB to assimilate the serum cholesterol into the cell 
membrane (Liong and Shah, 2005a and 2005b). The serum cholesterol level was also 
reduced via the production of bile salt hydrolase (BSH) by LAB (Lye et al., 2009). 
The hypercholesterolaemic effect of BSH was achieved via deconjugation of the bile 
salt, which limited re-absorption in the gut and facilitated excretion in faeces (Liong 
and Shah, 2005a and 2005b).  
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 LAB have also been found to lower the blood pressure level. The production 
of bioactive angiotensin-I converting enzyme (ACE) inhibiting peptides by LAB 
have been shown to affect the rennin-angiotensin system. One study showed that the 
administration of L. helveticus-fermented milk significantly reduced the systolic and 
diastolic blood pressure by 4.1 mm Hg and 1.8 mm Hg respectively. The production 
of ACE-inhibitory peptides was also significantly increased in cheese upon addition 
of LAB during the fermentation process (Rhyänen et al., 2001; Donkor et al., 2007; 
Ong and Shah, 2008).  
 In addition, the gastrointestinal tract colonising-LAB can produce various 
nutrients for the host. Gomes and Malcata (1999) reported that LAB synthesised 
various vitamins such as folic acid, niacin, thiamine, riboflavin, pyridoxine, 
cyanocobalamin, and vitamin K where these vitamins were slowly absorbed by the 
host. However, the ability to synthesise vitamins and the concentration of vitamins 
produced was strain dependent (Biavati and Mattarelli, 2006). Several studies have 
reported the ability of L. lactis and L. bulgaricus to produce higher amount of folic 
acid, niacin, biotin, pantothenic acid, vitamin B6 and vitamin B12 as compared to 
their unfermented counterparts (unfermented control)  (Hugenholtz and Kleerebezem, 
1999; Kleerebezem and Hugenholtz, 2003). 
 
 2.1.3 LAB for Dermal Health 
 Increasing evidences indicate the possible use of LAB for treating extra-
intestinal disorders by maintaining the intestinal microbiota balance, and thus 
ameliorating the immune system at local and systemic levels. The use of LAB to 
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exert health benefits beyond the gut through the gut-brain-skin axis hypothesis was 
proposed by Arck et al. (2010).  
 The potential roles of LAB to promote dermal health have been highlighted 
by numerous studies. LAB act as immune-modulators and improve skin health by 
regulating the production of cytokines and growth factors such as tumor-necrosis 
factor-alpha (TNF-α), interferon-gamma (IFN-Ɣ), transforming growth factor (TGF), 
and immunoglobulins (IgA and IgE). Guéniche et al. (2009) have reported that the 
ingestion of L. johnsonii NCC533 daily for 8 weeks significantly increased the 
production of cytokines and TGF-β, resulting in the preservation of cutaneous 
immune homeostasis in 57 volunteers upon exposure to ultraviolet ray of 2 x 1.5 
minimal erythema dose. In addition, several studies have demonstrated alleviation of 
cow milk allergy and atopic dermatitis (AD) lesions via the consumption of L. 
rhamnosus GG. Upon administration, the level of IL-10 and IFN-Ɣ was significantly 
increased, resulting in preservation of cutaneous homeostasis (Pessi et al., 2000; 
Pohjavouri et al., 2004). Recently, the consumption of probiotics for 6 months was 
shown to reduce the risk of Ig-E- associated atopic eczema of the subjects (mothers 
at 35 weeks of gestation age and continued after the birth of infants up to the age of 6 
months) via interaction with the neuropeptide S receptor 1 gene SNP hopo546333 
(Kauppi et al., 2014).  
Besides promoting dermal health through the gut-skin axis, LAB have been 
employed in topical applications that exert dermal-promoting effects directly on the 
skin. One animal study has reported that wound closure and healing were 
significantly accelerated in the ischaemic and infected wounds of New Zealand 
white rabbits upon treatment with an adhesive gas permeable patch containing nitric 
oxide gas-producing probiotics (Figure 2.1; Jones et al., 2012).   
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Figure 2.1 Photographs of infected full-thickness dermal wounds on ears that are 
either ischaemic “I” or non-ischaemic “N” and treated with nitric oxide gas-
producing probiotic patchers or treated with vehicle control patches at days 1, 13 and 
20 post-surgery. Wound healing was monitored daily and photographic records were 
kept for computer-aided morphometric analysis. Reprinted from Jones et al. (2012); 
with permission from John Wiley and Sons (License number: 3791820268326). 
 
 Dermal health can be improved not only by using whole LAB cells but also 
by using bioactive metabolites from LAB. Lysate from Lactobacillus and 
Bifidobacterium modulated the protein components such as claudin 3 of 
keratinocytes and increased the tight-junction (Sultana et al., 2013), while L. 
helveticus-fermented milk promoted keratinocyte cell differentiation via 
enhancement of keratin-10 mRNA expression (Baba et al., 2006). Another study has 
also suggested that bioactive metabolites produced by LAB such as bacteriocins and 
lipoteichoic acid (LTA) could kill skin pathogens and promote the host skin defence 
system (Tan et al., 2014). 
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2.1.4 LAB-Derived Bioactive Metabolites for Dermal Health 
  2.1.4(a) Lactic Acid 
 LAB ferment carbohydrates via the Embden-Meyerhof-Panas pathway and 
produce lactic acid as the major metabolic end product. LAB also use the 6-P-
gluconate/phosphoketolase pathway for carbohydrate fermentation, and produce 
lactic acid, acetic acid/ethanol and carbon dioxide as the end products (König and 
Fröhlich, 2009). There are two optical isomer forms of lactic acid, namely the L-(+)-  
and D-(-)-lactic acid.  
Besides its antimicrobial ability, lactic acid has also demonstrated profound 
effects on epidermal and dermal layers by stimulating the secretion of cytokines. 
Topical application of 5 % lactic acid lotion over a year in 22 acne patients 
illustrated a significant reduction in inflammatory lesion counts and comedones 
(Garg et al., 2002). Another study by Rendl et al. (2001) demonstrated that the 
secretion of vascular endothelial growth factor (VEGF) was significantly increased 
after the topical application of 1.5-3.0 % of lactic acid over the skin; subsequently 
wound repair was improved via stimulation of endothelial cells proliferation and 
migration and the expression of angiogenesis-related genes. In addition, lactic acid 
also enhanced the production of IL-17a that subsequently increased the re-
epithelisation of skin wound healing, regardless of IL-23 dependent or independent 
pathway (Tesmer et al., 2008; Yabu et al., 2010). Lactic acid has also been used as a 
chemical peeling agent and exfoliator for different skin conditions. Another study 
has demonstrated a significant reduction of lengtigines and mottled hyper-
pigmentation in the left forearm of a 62-year-old subject after the topical treatment 
of 25 % lactic acid twice daily for 6 months, as compared to the right forearm 
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(placebo; Green et al., 2009). Sachdeva (2010) reported that treatment with 95 % 
(pH 2.0) lactic acid on seven patients of age 20-30 with superficial acne scaring for 
three months significantly improved the texture, pigmentation, and appearance of the 
treated skin with lightening of scars (Figure 2.2). 
Figure 2.2 A 23-year-old female, Fitzpatrick skin type IV, (a) with comedonal acne 
and superficial acne scarring on the left side of the face, and (b) after four chemical 
peels with lactic acid showing good improvement, 3 months after treatment. 
Reprinted from Sachdeva (2010); with permission from John Wiley and Sons 
(License number: 3792311215214). 
 
  2.1.4(b) Acetic Acid 
 In addition to lactic acid, acetic acid produced by heterofermentative LAB 
such as L. buchneri is also known to improve dermal health. Numerous studies have 
suggested the potential use of acetic acid as topical antibacterial agents, especially in 
superficial wounds. The bactericidal effect of acetic acid was due to the chemical 
action of acetic acid itself which lowered the surrounding pH to a range that was 
unsuitable for the growth of pathogens (Nagoba et al., 2008). Ryssel et al. (2009) 
demonstrated that 3 % acetic acid actively inhibited the growth of both Gram-
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positive and Gram-negative pathogenic bacteria commonly found in burn units. In 
this study, acetic acid was capable of inhibiting the growth of P. aeruginosa upon 5 
min treatment while the growth of Gram-positive S. aureus and S. epidermidis was 
completely inhibited upon 30 min treatment. Acetic acid was also able to inhibit the 
growth of Escherichia coli, Enterococcus feacalis and methicillin- resistant 
Staphylococcus aureus upon 60 min treatment. Another report has shown that the 
mean number of S. aureus and Gram-negative rods per ulcer were significantly 
reduced in 45 venous leg ulcer patients upon treatment with gauze dressing 
containing 0.25 % acetic acid (Hansson and Faergemann, 1995). Topical application 
of 3-5 % acetic acid daily for 12 days on seven hospitalised patients with diabetic  
foot ulcers successfully eliminated P. aeruginosa from the wounds, and a second 
application healed the wounds without grafting (Nagoba et al., 2008). 
 
  2.1.4(c) Bacteriocins 
 Bacteriocins are small, ribosomal synthesised antimicrobial peptides (AMPs) 
that exhibit either broad or narrow spectrum of antimicrobial activity. LAB have 
been well- documented for bacteriocin production (O’Sullivan et al., 2002; Reid et  
al., 2003). One study has been reported that a bacteriocin (3.4 kDa) produced by 
Lactococcus sp. HY 449 inhibited the growth of numerous skin inflammatory 
bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus, 
Propionibacterium acnes, and Streptococcus pyrogenes (Oh et al., 2006). In addition, 
the bacteriocin from Lactococcus lactis KU24 exhibited significant inhibitory effect 
against methicillin- resistant S. aureus, indicating the potential application of 
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bacteriocin as an alternative antimicrobial agent against the growing number of 
antibiotic-resistant pathogens (Cotter et al., 2013; Lee et al. 2013). 
 In addition to direct antimicrobial activity against skin pathogens, 
bacteriocins have also been shown to modulate the host skin immune system. 
Marzani et al. (2012) reported that plantaricin A from L. plantarum promoted the 
antioxidant defences, barrier functions, and antimicrobial activity of the skin by 
enhancing the mRNA expression of filaggrin, involucrin, β-defensin 2, and TNF-α. 
In addition, plantaricin A was also reported to accelerate the wound healing process 
by increasing the expression of TGF-β1, VEGF-A, and IL-8, resulting in 
proliferation and migration of human keratinocytes (Pinto et al., 2011). Bacteriocins 
have also been incorporated into nanofibre scaffolds for dermal applications. Heunis 
et al. (2013) demonstrated that the number of viable S. aureus and the excision 
wound closure were significantly reduced on adult male BALB/c mice infected with 
S. aureus (Figure 2.3). 
Figure 2.3 Efficacy of nisin-eluting electrospun nanofibre blend of Poly(ethylene 
oxide) (PEO) and Poly(D,L- lactide) (PDLLA) of ratios (50:50) wound dressings to 
reduce Staphylococcus aureus Xen 36 bioluminescence in vivo in a full- thickness 
excisional skin wound model in mice. Bioluminescent images (A) and 
bioluminescent measurements (B) of mice infected with 10 µl of 108 CFU/ml S. 
aureus Xen 36 and treated with nisin-containing PEO 50 –PDLLA 50 nanofiber 
wound dressings (NFG) and control PEO 50 –PDLLA 50 nanofiber wound dressings 
(CFG). *, P<0.0001 compared to CFG. Error bars represent standard deviations. 
Reprinted from Heunis et al. (2013) with permission from American Society for 
Microbiology (ASM). 
18 
 
  2.1.4(d) Other Bioactive Metabolites 
 LAB are also capable of producing diacetyl, an organic compound with 
buttery flavour, as a metabolic by-product from citrate metabolism (Tan et al., 2014). 
Diacetyl exerts a broad antimicrobial spectrum against both Gram-positive and 
Gram-negative skin pathogens (Jay, 1982). The exact mode of antimicrobial action 
of diacetyl is scarcely reported and still remains unclear. Ho lzapfel et al. (2003) 
suggested that the binding of diacetyl to guanidino sites of arginine in bacterial 
enzymes and inactivation of the protein via blockage or modification of the catalytic 
regions were the main attribute to the antimicrobial action of diacetyl. In one study, 
the growth of E. coli and S. aureus was significantly inhibited by 2.43 and 4.23 times 
respectively in the broth culture medium supplemented with 300 ppm of diacetyl, as 
compared to the untreated cells (Lanciotti et al., 2003). Numerous in vitro studies 
have demonstrated the dermal potential of diacetyl; however, there are limited 
reports on the topical treatment of diacetyl for skin infections caused by skin 
pathogens in animal and clinical studies. 
 Besides diacetyl, LAB are also capable of producing hydrogen peroxide 
(H2O2). H2O2, a strong oxidiser generated by L. gasseri and L. johnsonnii NCC 533, 
significantly inhibited the growth of S. aureus and Salmonella sp. under aerobic 
conditions (Otero and Nader-Macias, 2006; Pridmore et al., 2008). In addition to 
antimicrobial activity, numerous evidences have also reported the wound healing 
effects of H2O2. Sen et al. (2002) demonstrated that H2O2 at 250 µM facilitated 
angiogenesis by activating the transcriptional factor Sp1 and inducing the mRNA 
expression of VEGF in human keratinocytes. In a clinical study involving 60 patients 
with mild to moderate acne vulgaris, the inflammatory and non- inflammatory lesions 
were significantly reduced in subjects with topical application of stabilised H2O2 
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cream, resulting in better local tolerability profiles (erythema, dryness and burning 
sensation), as compared to the benzoyl peroxide gel (Milani et al., 2003). Another 
study in zebrafish reported that H2O2 at a concentration of more than 166 mM 
resulted in detrimental effects such as delayed wound healing due to an increase in 
oxidative lipid damages and decrease in connective tissue formation (Niethammer et 
al., 2009). Hence, it was suggested that the concentration of H2O2 lower than 166 
mM could be safely applied to facilitate the wound healing process by enhancing the 
angiogenesis activity (Niethammer et al., 2009). 
 LAB such as L. rhamnosus and L. gasseri also capable of producing 
hyaluronic acid (HA), which is an essential component of the extracellular matrix 
(ECM) of skin required for maintaining the normal skin structure of stratum corneum 
(SC), conserving epidermal barrier functions, and influencing cell proliferation, 
differentiation and tissue repair (Gold, 2007; Kogan et al., 2007). It is a linear, 
anionic, and non-sulphated glycosaminoglycan polysaccharide comprised of D-
glucuronic acid and N-acetylglucosamine monomer units. The high hydrophilic 
property of HA was shown to improve skin hydration and elasticity (Gold, 2007). In 
addition, HA was also shown to reduce wrinkle depth in 76 female subjects aged 30 
to 60 years old after treatment with 0.1 % HA cream-based formulations (MW of 50, 
130, 300, 800 and 2000 kDa, respectively) for 60 days (Pavivic et al., 2011). HA 
was also shown to promote wound healing via enhancement of collagen deposition, 
cell proliferation, migration, angiogenesis, and pro- inflammatory activity (Weindl et  
al., 2004). A clinical study involving 89 patients with one or several leg ulcers of 
venous or mixed venous origin treated with cotton gauze pad impregnated with 0.05 % 
HA demonstrated enhanced wound closure, healed ulcers rate, and reduced visual 
analogue scale, as compared to the placebo group (Humbert et al., 2013). 
20 
 
2.2 Skin Defence System 
 The human skin serves as a protective barrier against environmental 
challenges and microbial pathogen invasion. The tough outer SC layer consists of 
overlapping, thin, and completely flattened keratinised cells connected by 
intercellular lipids that restrict the invasion of pathogenic microorganisms and 
chemicals into the body (Zaidi and Lanigan, 2010). This protective effect is 
enhanced by the naturally dry keratinised cell layers which are unfavourable for the 
growth of microorganisms. In addition, the SC layer is equipped with desquamation 
ability to help remove pathogenic microorganisms and chemicals from the skin 
surface (Chiller et al., 2001; Zaidi and Laginan, 2010). The human skin immune 
system comes into play once the first line of defence is invaded. 
 The human skin defence mechanisms consist of the first line innate immunity, 
which involves the initial rapid pathogens clearance, and the second line adaptive 
immunity, which generates highly specific cytokines and antibodies, as well as 
immunological memory (Kang et al., 2006). Both innate and adaptive immune 
systems have a coordinated effort in contributing to an effective immune response, 
even though both immune systems serve distinct functions. 
 
 2.2.1 Innate Immune System 
 Keratinocytes, Langerhans cells, neutrophils, and macrophages, as well as the 
production of pre-formed non-specific and broadly specific effector molecules are 
the major immune cells that are involved in the innate immune system (Oppemheim 
et al., 2003). Upon invasion of pathogenic microorganisms, toll- like receptors (TLRs) 
and other PAMPs receptors recognise the pattern-associated molecule patterns 
